Autologous Hematopoietic Recovery after Unrelated Umbilical Cord Blood Transplantation with Myeloablative Conditioning for Acute Myelogenous Leukemia

Internal Medicine
Ayumi GomyoYoshinobu Kanda

Abstract

Autologous hematopoietic recovery after allogeneic hematopoietic cell transplantation (allo-HCT) is rare in patients who receive myeloablative conditioning (MAC). Autologous hematopoietic recovery suggests graft rejection, leading to concerns about subsequent disease relapse. We herein report a rare case of a patient with acute leukemia who experienced autologous hematopoietic recovery after cord blood transplantation (CBT) with total body irradiation-based MAC. Chromosomal abnormalities were repeatedly detected without any disease relapse for eight months. The accumulation of similar cases is required to accurately assess the incidence and clinical outcomes of autologous hematopoietic recovery after CBT with MAC.

References

Mar 1, 1994·Leukemia & Lymphoma·J MehtaS Allard
Mar 31, 2004·Experimental Hematology·Eliane GluckmanUNKNOWN Eurocord Group
Nov 17, 2009·Bone Marrow Transplantation·A PiccinUNKNOWN Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplantation
Jun 11, 2014·Blood·Boglarka Gyurkocza, Brenda M Sandmaier
Jun 28, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hisashi YamamotoShuichi Taniguchi
Nov 24, 2016·American Journal of Hematology·Hideki NakasoneUNKNOWN Complication Working Group of Japanese Society for Hematopoietic Cell Transplantation
May 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sandhya R PanchDavid F Stroncek
May 5, 2018·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Zehra Narli Ozdemir, Sinem Civriz Bozdağ
Jun 4, 2019·International Journal of Hematology·Hisashi Yamamoto
Dec 11, 2019·Bone Marrow Transplantation·Motohiro KatoUNKNOWN Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Medizinische Klinik
Hartmut GoldschmidtAnthony D Ho
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Henk B Kal, M Loes van Kempen-Harteveld
© 2022 Meta ULC. All rights reserved